Semax

Overview

Semax is a synthetic heptapeptide (seven amino acids) derived from a fragment of adrenocorticotropic hormone (ACTH), specifically the ACTH(4-10) region. It was developed in Russia and has decades of research history there, primarily in the context of stroke recovery and cognitive performance.

Proposed Mechanism

Increases brain-derived neurotrophic factor (BDNF) and modulates dopaminergic and serotonergic activity in the prefrontal cortex. Studied in Russia for stroke recovery and cognitive performance.

Research Context

The core research mechanism under study is Semax's effect on brain-derived neurotrophic factor (BDNF) and dopaminergic/serotonergic activity in the prefrontal cortex — brain regions and neurotransmitter systems closely tied to attention, planning, and mood regulation.

Evidence Status — Well-documented

Well-documented within Russian clinical literature; less independently replicated in Western trials.

Semax has a substantial body of clinical research behind it within Russian medical literature, including use in stroke rehabilitation settings. That body of evidence has not been extensively replicated in Western, English-language peer-reviewed trials, which is a meaningful gap for anyone trying to weigh the totality of available evidence rather than one research tradition's findings alone.

Research Use Only

This page is a scientific reference summarizing publicly available research literature. It contains no dosing, administration, or protocol guidance, and nothing here constitutes medical advice. BactoCore does not sell this or any peptide referenced in this index — the only product sold directly is bacteriostatic water. See the Safety section for who should not handle research compounds, and the Research Use Disclaimer for full terms.